Aytu Biopharma Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Aytu Biopharma Inc Company

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Aytu Biopharma Inc Info



Ticker SymbolAYTU

Company nameAytu Biopharma Inc

IPO dateOct 20, 2017

CEOMr. Joshua R. (Josh) Disbrow

Number of employees99

Security typeOrdinary Share

Fiscal year-endOct 20

Address7900 E. Union Avenue

CityDENVER

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code80237

Phone17204376580

Websitehttps://aytubio.com/

Ticker SymbolAYTU

IPO dateOct 20, 2017

CEOMr. Joshua R. (Josh) Disbrow

Company Executives of Aytu Biopharma Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

--

Mr. John A. Donofrio, Jr.

Independent Chairman of the Board

--

Mr. Joshua R. (Josh) Disbrow

Chief Executive Officer, Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

61.57K

+108.97%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

49.74K

+210.89%

Mr. Greg Pyszczymuka

Chief Commercial Officer

36.10K

+51.62%

Mr. Carl C. Dockery

Independent Director

21.15K

+89.67%

Ms. Vivian H. Liu

Independent Director

19.82K

+101.78%

Mr. Abhinav (Abi) Jian

Independent Director

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

ADHD portfolio

57.58M

86.73%

Pediatric portfolio

8.77M

13.21%

Other

37.00K

0.06%

Shareholding Stats

Updated: Thu, Oct 9

Shareholders

Shareholder Types

Shareholders

Proportion

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

7.98%

AWM Investment Company, Inc.

6.08%

Kanen Wealth Management, LLC

5.63%

Lytton (Laurence W)

4.97%

Other

64.67%

Shareholders

Proportion

Nantahala Capital Management, LLC

10.67%

Stonepine Capital Management, LLC

7.98%

AWM Investment Company, Inc.

6.08%

Kanen Wealth Management, LLC

5.63%

Lytton (Laurence W)

4.97%

Other

64.67%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

20.71%

Hedge Fund

11.92%

Individual Investor

9.18%

Investment Advisor

0.90%

Bank and Trust

0.03%

Other

57.27%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

61

3.42M

33.56%

+1.32M

2025Q2

68

3.25M

36.18%

+961.20K

2025Q1

66

2.05M

28.89%

-146.84K

2024Q4

71

2.05M

33.28%

-280.21K

2024Q3

75

2.20M

40.58%

-328.29K

2024Q2

78

2.26M

43.50%

-3.54K

2024Q1

82

1.99M

41.33%

-356.06K

2023Q4

85

1.96M

40.81%

-395.45K

2023Q3

91

1.92M

40.24%

-406.76K

2023Q2

100

1.89M

40.00%

+821.00K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Nantahala Capital Management, LLC

1.09M

10.96%

--

Jun 30, 2025

Stonepine Capital Management, LLC

812.68K

8.2%

+348.95K

+75.25%

Jun 30, 2025

AWM Investment Company, Inc.

619.87K

6.25%

+619.87K

--

Jun 30, 2025

Kanen Wealth Management, LLC

573.36K

5.78%

+407.09K

+244.84%

Jun 30, 2025

Lytton (Laurence W)

506.61K

5.11%

+506.61K

--

Jun 09, 2025

Disbrow (Joshua R.)

153.26K

1.71%

+66.67K

+76.99%

Jun 09, 2025

Renaissance Technologies LLC

89.91K

0.91%

+13.09K

+17.04%

Jun 30, 2025

Disbrow (Jarrett T)

29.46K

0.33%

+16.67K

+130.24%

Jun 09, 2025

Geode Capital Management, L.L.C.

53.87K

0.54%

-75.00

-0.14%

Jun 30, 2025

Selhorn (Ryan J)

16.00K

0.26%

--

Mar 24, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

DFA Dimensional US Sustainability Core 1 ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Date

Type

Ratio

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Jan 05, 2023

Merger

20→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1